Equitable access to cell and gene therapies in South Africa: opportunities and hurdles

Affiliations

¹ Institute for Cellular and Molecular Medicine, Department of Immunology, and South African Medical Research Council Extramural Unit for Stem Cell Research and Therapy, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa.
² Antion Biosciences SA, Geneva, Switzerland.
³ Institute for Cellular and Molecular Medicine, Department of Immunology, and South African Medical Research Council Extramural Unit for Stem Cell Research and Therapy, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa. michael.pepper@up.ac.za.

Review

Candice Laverne Hendricks et al. Gene Ther. 2023 Feb.

. 2023 Feb;30(1-2):180-186.

doi: 10.1038/s41434-021-00309-y. Epub 2022 Jan 8.

¹ Institute for Cellular and Molecular Medicine, Department of Immunology, and South African Medical Research Council Extramural Unit for Stem Cell Research and Therapy, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa.
² Antion Biosciences SA, Geneva, Switzerland.
³ Institute for Cellular and Molecular Medicine, Department of Immunology, and South African Medical Research Council Extramural Unit for Stem Cell Research and Therapy, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa. michael.pepper@up.ac.za.

No abstract available

References

1. 2020: Growth & Resilience in Regenerative Medicine—Alliance for Regenerative Medicine [Internet]. Alliance for Regenerative Medicine—Annual Report. 2020 [cited 2021 Jul 19]. https://alliancerm.org/sector-report/2020-annual-report/
1. Demartino P, Haag MB, Hersh AR, Caughey AB, Roth JA. A budget impact analysis of gene therapy for sickle cell disease: the medicaid perspective. JAMA Pediatr. 2021;97239:1–7. https://doi.org/10.1001/jamapediatrics.2020.7140 - DOI
1. Pepper MS, Alessandrini M, Pope A, van Staden W, Green RJ. Cell and gene therapies at the forefront of innovative medical care: Implications for South Africa. S Afr Med J. 2019;109:20–2. https://doi.org/10.7196/SAMJ.2019.v109i1.13425 - DOI
1. Jayaraman K. Cut-price CAR-T cell therapies top India’s biotech agenda. Nat Biotechnol. 2019;37:1388–9. https://doi.org/10.1038/s41587-019-0346-1 - DOI - PubMed
1. Munshi NC, Anderson LD, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384:705–16. https://doi.org/10.1056/NEJMoa2024850 - DOI - PubMed